As President Trump hails pricing agreements with the pharmaceutical industry, some biotech companies are worried they have been left out in the cold.

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

The European Directory of Biotechnology Companies offers key market opportunities by providing access to 2,000 biotech companies and 5,000 executives. It assists in pinpointing decision-makers, ...

The International Directory of Biotechnology Companies provides an essential resource for accessing key decision-makers globally, aiding in market profiling, business prospecting, and competitive ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

2026 could be a big year for this company.

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

NINGBO, ZHEJIANG, CHINA, January 21, 2026 /EINPresswire.com/ -- Ningbo Scientz Biotechnology Co., Ltd., a leading ...

First national call is LIVE for new biotech fund under the Centre’s RDI initiative, signalling India’s big bet on Bioeconomy ...